Selvita Group Received a GMP Certificate

selvita logo

Krakow, Poland, February 18, 2014 / B3C newswire / - Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, received a GMP certificate.

On February 11 2014, after positive inspection conducted by the Main Pharmaceutical Inspectorate (the competent authority of Poland granting GMP certificates), BioCentrum, a part of Selvita Group received a certificate of compliance with the principles of Good Manufacturing Practice (GMP).

GMP certificate was granted based on positive results of GMP inspection conducted on 19-20 November 2013. The range of GMP certificate covers all services offered by the Analytical Laboratory, including physical and chemical testing in quality control of the pharmaceutical products. This certificate was issued for 3 years.

Positive results of the GMP inspection confirmed that Selvita complies with the standards and requirements of the GMP in its routine activities and all studies conducted in Selvita Group, are planned, performed, monitored, and reported in accordance with the international quality standards established by the pharmaceutical industry.

"GMP certification is an extremely important event in the Selvita’s development. Obtaining the GMP certificate proves that the quality of research is one of the strategic objectives of our company. The GMP and GLP certificates confirm that our laboratories are working according to the highest worldwide quality standards. Thanks to the GLP/GMP quality system our company is more recognizable in the world, and the results generated by our scientists are credible and accepted by the registration authorities in other countries" - said Dr. Miłosz Gruca, Director of Research and Development, Board Member of BioCentrum Sp. z o.o.

Selvita Group Analytical Laboratory joined the elite group of five Polish laboratories certified in both GMP and GLP.

About Selvita
Selvita is the largest independent integrated drug discovery services provider in Central and Eastern Europe, based in Krakow, Poland. The company was established in 2007, and ever since its mission has been to serve our clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating, the introduction of new drugs to the market. The company employs over 180 people including 60 PhDs.
Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the NewConnect market of the Warsaw Stock Exchange in Poland (SLV).
For more information about the project or the company, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.    

Media contact
Paulina Wolanin
Phone: +48 668 111 456
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.